Total Payments
$252,278
2024 Payments
$29,104
Companies
24
Transactions
290
Medicare Patients
1,059
Medicare Billing
$43,757
Payment Breakdown by Category
Other$182,360 (72.3%)
Travel$30,761 (12.2%)
Consulting$28,527 (11.3%)
Food & Beverage$9,355 (3.7%)
Research$1,260 (0.5%)
Education$14.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $120,760 | 41 | 47.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $37,800 | 8 | 15.0% |
| Travel and Lodging | $30,761 | 89 | 12.2% |
| Consulting Fee | $28,527 | 12 | 11.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $23,800 | 5 | 9.4% |
| Food and Beverage | $9,355 | 130 | 3.7% |
| Unspecified | $1,260 | 4 | 0.5% |
| Education | $14.50 | 1 | 0.0% |
Payments by Type
General
$251,018
286 transactions
Research
$1,260
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $81,170 | 89 | $0 (2024) |
| ABBVIE INC. | $73,111 | 67 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $54,694 | 41 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $23,951 | 22 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $12,102 | 40 | $0 (2020) |
| Veloxis Pharmaceuticals, Inc. | $1,500 | 1 | $0 (2022) |
| Eli Lilly and Company | $1,260 | 4 | $0 (2020) |
| PFIZER INC. | $1,131 | 4 | $0 (2019) |
| Bayer HealthCare Pharmaceuticals Inc. | $1,100 | 1 | $0 (2017) |
| Ipsen Bioscience Inc. | $606.95 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $29,104 | 17 | ABBVIE INC. ($12,667) |
| 2023 | $15,116 | 10 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($10,340) |
| 2022 | $15,971 | 26 | ABBVIE INC. ($8,855) |
| 2021 | $26,792 | 23 | AbbVie Inc. ($18,986) |
| 2020 | $20,724 | 25 | AbbVie Inc. ($7,840) |
| 2019 | $48,745 | 66 | AbbVie, Inc. ($20,866) |
| 2018 | $52,721 | 67 | Gilead Sciences, Inc. ($40,849) |
| 2017 | $43,105 | 56 | Valeant Pharmaceuticals North America LLC ($23,951) |
All Payment Transactions
290 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,750.00 | General |
| Category: Gastroenterology | ||||||
| 12/16/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,150.00 | General |
| Category: INFLAM | ||||||
| 12/12/2024 | Gilead Sciences, Inc. | Livdelzi (Drug) | Food and Beverage | In-kind items and services | $96.55 | General |
| Category: INFLAM | ||||||
| 12/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $122.06 | General |
| Category: Gastroenterology | ||||||
| 12/10/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $49.39 | General |
| Category: Gastroenterology | ||||||
| 11/18/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $71.70 | General |
| Category: LIVER DISEASE | ||||||
| 10/10/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $6,750.00 | General |
| Category: Gastroenterology | ||||||
| 10/09/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $103.95 | General |
| Category: Gastroenterology | ||||||
| 09/10/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $136.00 | General |
| Category: LIVER DISEASE | ||||||
| 08/02/2024 | ABBVIE INC. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: VIROLOGY | ||||||
| 07/09/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $2.71 | General |
| Category: SURGERY | ||||||
| 06/18/2024 | ABBVIE INC. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,500.00 | General |
| Category: VIROLOGY | ||||||
| 06/02/2024 | SANOFI-AVENTIS U.S. LLC | — | Food and Beverage | In-kind items and services | $146.39 | General |
| 05/28/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $58.48 | General |
| Category: Gastroenterology | ||||||
| 05/08/2024 | ABBVIE INC. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: VIROLOGY | ||||||
| 03/01/2024 | ABBVIE INC. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,900.00 | General |
| Category: VIROLOGY | ||||||
| 02/07/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $66.95 | General |
| Category: VIROLOGY | ||||||
| 12/12/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $6,300.00 | General |
| Category: Gastroenterology | ||||||
| 11/29/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $122.01 | General |
| Category: Gastroenterology | ||||||
| 11/07/2023 | ABBVIE INC. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,875.00 | General |
| Category: VIROLOGY | ||||||
| 10/23/2023 | ABBVIE INC. | MAVYRET (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,875.00 | General |
| Category: VIROLOGY | ||||||
| 10/21/2023 | Ipsen Bioscience Inc. | — | Travel and Lodging | In-kind items and services | $606.95 | General |
| 10/12/2023 | Penumbra, Inc. | RUBY Coil (Device) | Food and Beverage | Cash or cash equivalent | $134.00 | General |
| Category: Peripheral Intervention | ||||||
| 09/27/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Compensation for serving as faculty or as a speaker for a medical education program | Cash or cash equivalent | $3,500.00 | General |
| Category: Gastroenterology | ||||||
| 09/25/2023 | Boston Scientific Corporation | TheraSphere Y90 Glass Microspheres 10 GBq (Device) | Food and Beverage | In-kind items and services | $165.47 | General |
| Category: TheraSphere_PI | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $681.33 | 2 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $579.01 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 355 | 378 | $43,733 | $13,550 |
| 2022 | 4 | 250 | 273 | $31,836 | $11,514 |
| 2021 | 4 | 243 | 272 | $25,924 | $10,178 |
| 2020 | 3 | 211 | 232 | $22,151 | $8,516 |
Total Patients
1,059
Total Services
1,155
Medicare Billing
$43,757
Procedure Codes
20
All Medicare Procedures & Services
20 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 68 | 87 | $17,913 | $6,145 | 34.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 28 | 28 | $11,116 | $3,215 | 28.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 21 | 21 | $6,007 | $1,994 | 33.2% |
| 91200 | Measurement of liver stiffness | Facility | 2023 | 225 | 229 | $6,837 | $1,648 | 24.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 13 | 13 | $1,860 | $547.52 | 29.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 62 | 76 | $13,525 | $5,259 | 38.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 27 | 27 | $9,535 | $3,273 | 34.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 13 | 17 | $4,285 | $1,876 | 43.8% |
| 91200 | Measurement of liver stiffness | Facility | 2022 | 148 | 153 | $4,491 | $1,107 | 24.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 67 | 93 | $15,602 | $6,567 | 42.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 11 | 11 | $3,627 | $1,460 | 40.3% |
| 91200 | Measuring the stiffness in the liver via elastography | Facility | 2021 | 133 | 136 | $3,996 | $1,062 | 26.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 19 | 19 | $2,170 | $911.27 | 42.0% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2021 | 13 | 13 | $529.00 | $176.75 | 33.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 39 | 48 | $8,208 | $2,882 | 35.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 31 | 36 | $6,156 | $2,783 | 45.2% |
| 91200 | Measuring the stiffness in the liver via elastography | Facility | 2020 | 97 | 99 | $2,823 | $957.41 | 33.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 19 | 24 | $2,764 | $908.99 | 32.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 11 | 11 | $1,276 | $641.38 | 50.3% |
| 91200 | Measuring the stiffness in the liver via elastography | Office | 2020 | 14 | 14 | $924.00 | $342.87 | 37.1% |
About Dr. Richard Gilroy, MD
Dr. Richard Gilroy, MD is a Gastroenterology healthcare provider based in Salt Lake City, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1255389060.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Gilroy, MD has received a total of $252,278 in payments from pharmaceutical and medical device companies, with $29,104 received in 2024. These payments were reported across 290 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($120,760).
As a Medicare-enrolled provider, Gilroy has provided services to 1,059 Medicare beneficiaries, totaling 1,155 services with total Medicare billing of $43,757. Data is available for 4 years (2020–2023), covering 20 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Salt Lake City, UT
- Active Since 05/04/2006
- Last Updated 10/08/2025
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1255389060
Products in Payments
- XIFAXAN (Drug) $78,503
- Epclusa (Drug) $54,507
- MAVYRET (Drug) $48,348
- Mavyret (Drug) $21,012
- LJN452 (Drug) $7,672
- Livdelzi (Drug) $5,247
- Vosevi (Drug) $4,158
- Envarsus (Drug) $1,500
- ZORTRESS (Drug) $1,468
- Stivarga (Drug) $1,100
- RESMETIROM (Drug) $207.70
- TheraSphere Y90 Glass Microspheres 10 GBq (Device) $165.47
- ECHELON ENDOPATH Stapler (Device) $137.60
- RUBY Coil (Device) $134.00
- Wako HCC Biomarker(s) DCP and AFP-L3 (Device) $127.09
- OCALIVA (Drug) $119.39
- OCA (Drug) $118.32
- STRATAFIX (Device) $105.78
- SOLID ORGAN TRANSPLANT (Drug) $84.88
- SIR-Spheres Microspheres (Device) $79.59
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Salt Lake City
Kathryn Peterson, Md, MD
Gastroenterology — Payments: $94,047
Gastroenterology $94,047
Dr. Peder Pedersen, M.d, M.D
Gastroenterology — Payments: $67,521
Gastroenterology $67,521
Amir Kashani
Gastroenterology — Payments: $43,637
Gastroenterology $43,637
Dr. Juan Gallegos-Orozco, M.d, M.D
Gastroenterology — Payments: $30,877
Gastroenterology $30,877
Iqbal Sandhu, Md, MD
Gastroenterology — Payments: $18,270
Gastroenterology $18,270
John Fang, Md, MD
Gastroenterology — Payments: $14,387
Gastroenterology $14,387